Skip to main content
Premium Trial:

Request an Annual Quote

InterWest Health Providing its Members Access to Genetic Technologies' Breast Cancer Test

NEW YORK (GenomeWeb News) – Genetic Technologies today announced an agreement with InterWest Health to provide the preferred provider organization's members access to GTG's BrevaGen breast cancer diagnostic test.

The deal is the eighth that Melbourne, Australia-based GTG has reached with a US PPO. The deal was forged between its wholly owned subsidiary Phenogen Sciences and InterWest, a regional provider network based in Missoula, Mont. servicing seven states in the northwest US. InterWest's network includes more than 15,000 health care providers, GTG said.

Before today's announcement, GTG in June inked a similar agreement with FedMed. GTG said that more than 102 million lives now have access to BrevaGen as an in-network benefit.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.